Who is Steven H. Collis and what is his background relevant to Elevance Health?

The filing does not provide extensive background details on Steven H. Collis. However, it highlights his qualification as an 'audit committee financial expert,' suggesting significant experience in financial matters and oversight. Investors can refer to the press release (Exhibit 99.1) for more biographical information or look to his public profile for further details on his career.

What is the significance of Mr. Collis's appointment to the Audit and Finance Committees?

His appointment to these committees signifies his critical role in overseeing the company's financial reporting, internal controls, and financial strategy. As an 'audit committee financial expert,' he is expected to provide enhanced financial scrutiny and guidance, which is crucial for investor confidence and sound corporate governance.

How will Steven H. Collis be compensated for his role as a director?

Mr. Collis will be compensated according to Elevance Health's standard compensation program for non-employee directors. Details of this compensation plan are available in Exhibit 10.7 of the company's Quarterly Report on Form 10-Q for the quarter ended June 30, 2025.

Are there any potential conflicts of interest with Mr. Collis's appointment?

The filing explicitly states that there are no arrangements or understandings with other persons regarding his election, and Mr. Collis has no direct or indirect material interest in any transaction requiring disclosure under Item 404(a) of Regulation S-K. This suggests the company has taken steps to ensure no immediate conflicts of interest.

ELV 8-K: Leadership Changes

Summary

Elevance Health, Inc. (ELV) announced a change to its Board of Directors through an 8-K filing dated July 28, 2025. The company elected Steven H. Collis as an independent director, effective August 1, 2025, with his term set to conclude at the 2027 annual shareholder meeting. This appointment is a key governance update that investors should note, particularly given Mr. Collis's qualifications and committee assignments. Mr. Collis brings valuable expertise to the Board, as evidenced by his appointment to both the Audit and Finance Committees. Notably, he has been designated as an "audit committee financial expert" by the SEC, suggesting a strong financial acumen that can contribute to oversight of the company's financial reporting and internal controls. His compensation will align with the company's existing non-employee director compensation structure.

Key Highlights

1Steven H. Collis elected as an independent director to the Board, effective August 1, 2025.
2Mr. Collis's term as a director will expire at the 2027 annual shareholder meeting.
3Appointment to key Board committees: Audit and Finance Committees.
4Designated as an 'audit committee financial expert,' indicating strong financial oversight capabilities.
5No undisclosed arrangements or material interests in transactions requiring Regulation S-K disclosure.
6Compensation for Mr. Collis will follow the standard program for non-employee directors.

Elevance Health, Inc. 8-K Report, Executive Changes (Jul 28, 2025)

Summary

Key Highlights

Frequently Asked Questions